- Home
- CRT vs MREO Comparison
CRT vs MREO Comparison
Compare CRT & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRT | MREO |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United Kingdom |
| Employees | 2 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.1M | 53.4M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | CRT | MREO |
|---|---|---|
| Price | $9.66 | $0.31 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 20.6K | ★ 1.5M |
| Earning Date | 04-14-2026 | 05-11-2026 |
| Dividend Yield | ★ 5.29% | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | N/A | $5,184.20 |
| Revenue Next Year | N/A | $55.51 |
| P/E Ratio | $11.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.07 | $0.20 |
| 52 Week High | $11.10 | $2.37 |
Technical Indicators
Market Signals| Indicator | CRT | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 56.75 | 47.17 |
| Support Level | $9.29 | $0.28 |
| Resistance Level | $10.11 | $0.35 |
| Average True Range (ATR) | 0.26 | 0.02 |
| MACD | 0.14 | -0.00 |
| Stochastic Oscillator | 82.08 | 12.20 |
Price Performance
Historical ComparisonAbout CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).